Article
Hematology
Alexandros Rampotas, Matthew R. Wilson, Oliver Lomas, Nicholas Denny, Heather Leary, Graeme Ferguson, Pamela McKay, Tim Ebsworth, Jonathan Miller, Nimish Shah, Nicolas Martinez-Calle, Mark Bishton, Angharad Everden, David Tucker, Ezzat El-Hassad, Brian Hennessy, Dearbhla Doherty, Steve Prideaux, Rehman Faryal, Amjad Hayat, Clodagh Keohane, Helen Marr, Adam Gibb, Rachael Pocock, Jonathan Lambert, Rachel Lacey, Nagah Elmusharaf, Ruth Clifford, Toby A. Eyre
Summary: This study looked at the outcomes of attenuated immunochemotherapy in elderly, unfit patients with mantle cell lymphoma. The study found that the median progression-free survival was 15 months, and that higher treatment intensity provided a better progression-free survival compared to lower intensity regimens. Overall, survival after front-line dose-attenuated immunochemotherapy was found to be unsatisfactory, indicating a need for further research on novel agents in this specific clinical setting.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Review
Hematology
Elisabeth Silkenstedt, Kim Linton, Martin Dreyling
Summary: Mantle cell lymphoma (MCL) exhibits heterogeneous behavior, with treatment options needing to be tailored based on individual risk profiles for optimal outcomes. Recent advances in understanding the molecular background of MCL have led to innovative therapies and improved treatment recommendations for primary and relapsed/refractory MCL.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Ping Yang, Qing-qing Cai, Wei Zhang, Shuo-zi Liu, Hui Liu, Xiu-hua Sun, Yu-jun Dong, Xiu-bin Xiao, Jing-wen Wang, Zhen-ling Li, Wen-rong Huang, Li-hong Li, Hui-zheng Bao, Wei Yang, Ya-lan Wang, Shu-ye Wang, Juan He, Xiao-ling Li, Ai-chun Liu, Hong-mei Jing
Summary: This study aimed to explore the clinical characteristics, treatment patterns, and prognosis of Mantle cell lymphoma (MCL) patients in China. The findings showed that high-dose cytarabine and auto-SCT as consolidation therapy improved the survival rates of MCL patients. Additionally, maintenance treatment and new drug therapies showed potential value in relapsed/refractory MCL patients.
Article
Cell Biology
Alexander D. Heini, Ulrike Bacher, Naomi Porret, Gertrud Wiedemann, Myriam Legros, Denise Stalder Zeerleder, Katja Seipel, Urban Novak, Michael Daskalakis, Thomas Pabst
Summary: This study reports two cases of mantle cell lymphoma patients who relapsed after CAR T therapy and were treated with the bispecific CD20/CD3 T cell engaging antibody glofitamab. Both patients showed increased circulating CAR T cells and objective responses after glofitamab administration. Therapy with bispecific antibodies might offer an effective and well-tolerated option for patients with mantle cell lymphoma relapsing after CAR T therapy.
Article
Oncology
Kossi D. Abalo, Karin E. Smedby, Sara Ekberg, Sandra Eloranta, Simon Pahnke, Alexandra Albertsson-Lindblad, Mats Jerkeman, Ingrid Glimelius
Summary: MCL survivors have an increased risk of secondary malignancies, especially if treated with R-bendamustine. The intensive treatments needed for long-term remissions are a concern, and transition to treatment protocols with sustained efficacy but with a lower risk of SM is needed.
EUROPEAN JOURNAL OF CANCER
(2023)
Letter
Oncology
Nobuhiko Nakamura, Senji Kasahara, Junichi Kitagawa, Hiroshi Nakamura, Michio Sawada, Kenji Fukuno, Yuhei Shibata, Yuto Kaneda, Takeshi Hara, Nobuhiro Kanemura, Hisashi Tsurumi, Masahito Shimizu
Summary: This study aimed to evaluate the efficacy and safety of BRAC combination therapy in patients with relapsed or refractory follicular lymphoma or mantle cell lymphoma. The results showed that BRAC therapy had a good response rate but also caused significant hematological toxicity.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Review
Oncology
Meri Tarockoff, Teresita Gonzalez, Stanislav Ivanov, Jose Sandoval-Sus
Summary: This review summarizes the current treatment strategies for R/R MCL, discusses evolving agents, and provides guidance in treating this complex disease. Advancements in targeted therapy, cellular therapies, and novel therapeutic agents show promising results for refractory and relapsed mantle cell lymphoma.
CURRENT ONCOLOGY REPORTS
(2022)
Article
Hematology
Peter A. Riedell, Mehdi Hamadani, Kwang W. Ahn, Carlos Litovich, Claudio G. Brunstein, Amanda F. Cashen, Jonathon B. Cohen, Narendranath Epperla, Brian T. Hill, Annie Im, David J. Inwards, John Lister, John M. McCarty, Sai Ravi Kiran Pingali, Mazyar Shadman, Paul Shaughnessy, Melhem Solh, Patrick J. Stiff, Julie M. Vose, Mohamed A. Kharfan-Dabaja, Alex F. Herrera, Craig S. Sauter, Sonali M. Smith
Summary: In young and fit patients with mantle cell lymphoma, intensive induction therapy followed by autologous haematopoietic cell transplant is the standard care. Time to relapse after autoHCT has a significant impact on overall survival, with early relapse defining a high-risk group with inferior post-relapse survival. This study highlights the importance of considering novel therapeutic approaches for MCL patients suffering early relapse after upfront autoHCT.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Yuqin Song, Keshu Zhou, Dehui Zou, Dengju Li, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Daobin Zhou, Constantine S. Tam, David Simpson, Michael Wang, Tycel J. Phillips, Stephen Opat, Cheng Fang, Shaohui Sun, Jun Zhu
Summary: The results of this study indicate that the use of zanubrutinib in second-line treatment of relapsed or refractory MCL is significantly associated with improved overall survival compared to later-line treatment. Other outcomes such as progression-free survival were similar between the two groups.
Article
Oncology
Dongfeng Zeng, Yu Fang, Yue Fei, Rong Liang, Haige Ye, Yun Liang, Xiuhua Sun, Michael Wang, Huiqiang Huang, Lugui Qiu, Yuxuan Che, Panpan Liu, Yi Wang, Tao Pan, Yao Lv, Jintai Deng, Shuhua Yi, Yizi He, Ling Xiao, Huijuan Lv, Jiangfang Feng, Huilai Zhang, Hui Zhou, Dehui Zou, Qingqing Cai
Summary: A real-world multicenter study conducted in China evaluated treatment patterns and outcomes in newly diagnosed MCL patients treated with BTK inhibitors. The study found that non-HD-AraC chemotherapy combined with BTK inhibitors may be a viable therapeutic strategy for younger patients, and anti-HBV prophylaxis should be implemented in patients with resolved hepatitis B.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Tao Wang, Wenqin Yue, Gusheng Tang, Mingyu Ye, Jiechen Yu, Bin Liu, Lijuan Jiao, Xuefei Liu, Shuyi Yin, Jie Chen, Lei Gao, Jianmin Yang, Miaoxia He
Summary: SAMHD1 is a protein that regulates innate immunity and DNA damage signaling, with high expression positively correlated with lower chemotherapy response rate and shorter overall survival in mantle cell lymphoma (MCL) patients, serving as an adverse biomarker. Silencing the SAMHD1 gene in MCL cell lines reduces cell proliferation and increases apoptosis, as well as enhances sensitivity to cytarabine. Four previously unreported missense mutations in the SAMHD1 gene were detected, although their biological functions remain to be elucidated.
FRONTIERS IN ONCOLOGY
(2021)
Article
Hematology
Minna Harmanen, Mika Hujo, Reijo Sund, Marc Sorigue, Madiha Khan, Roosa Prusila, Tuula Klaavuniemi, Esa Kari, Esa Jantunen, Kaisa Sunela, Aino Rajamaki, Erika Alanne, Hanne Kuitunen, Juan-Manuel Sancho, Arja Jukkola, Aino Ronka, Outi Kuittinen
Summary: Mantle cell lymphoma (MCL) is a rare peripheral B-cell lymphoma with a high rate of relapse and progression. The introduction of rituximab- and cytarabine-based immunochemotherapy regimens has significantly improved the prognosis of MCL over the past two decades. A population-based cohort study of 564 MCL patients diagnosed and treated between 2000 and 2020 showed a 2-year overall survival rate of 77%, a 5-year survival rate of 58%, and a 10-year survival rate of 32%. Disease progression within 24 months of initial diagnosis is a strong indicator of poor prognosis.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Hematology
Jeff Sharman, Shaum M. Kabadi, Jamyia Clark, David Andorsky
Summary: The study found that patients with mantle cell lymphoma treated with ibrutinib in community oncology practices had similar survival outcomes compared to clinical trials. The majority of patients discontinued treatment due to disease progression or toxicities.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Review
Oncology
Hailing Liu, Xiao Shi, Huizi Fang, Lei Cao, Yi Miao, Xiaoli Zhao, Wei Wu, Wei Xu, Jianyong Li, Lei Fan
Summary: This study systematically reviewed the use of autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma (MCL) and found that the benefit of ASCT has been weakened in the era of rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HiDAC) treatment. Alternative first-line maintenance strategies should be explored.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Kai Kroeger, Jan Siats, Andrea Kerkhoff, Georg Lenz, Matthias Stelljes, Hans Theodor Eich, Gabriele Reinartz
Summary: This study analyzed the long-term outcome of 22 patients with mantle cell lymphoma who underwent total body irradiation (TBI)-based conditioning prior to stem cell transplantation (SCT). The results support the effectiveness of TBI-based high-dose therapy followed by SCT in this unfavorable disease. The use of recently approved agents and traditional SCT opens up possibilities for personalized treatment for MCL.
Article
Oncology
Colombe Saillard, Helene Guermouche, Coralie Derrieux, Julie Bruneau, Laurent Frenzel, Lucile Couronne, Vahid Asnafi, Elizabeth Macintyre, Amelie Trinquand, Ludovic Lhermitte, Thierry Molina, Felipe Suarez, Francois Lemonnier, Olivier Kosmider, Richard Delarue, Olivier Hermine, Morgane Cheminant
HEMATOLOGICAL ONCOLOGY
(2017)
Letter
Dermatology
N. Kirsten, E. Tournier, B. Lepage, L. Lamant, O. Hermine, C. Paul, C. Bulai Livideanu
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2017)
Article
Oncology
M-T Rubio, M. Bouillie, N. Bouazza, T. Coman, H. Trebeden-Negre, A. Gomez, F. Suarez, D. Sibon, A. Brignier, E. Paubelle, S. Nguyen-Khoc, M. Cavazzana, O. Lantz, M. Mohty, S. Urien, O. Hermine
Article
Allergy
Vincent Barlogis, Nizar Mahlaoui, Pascal Auquier, Isabelle Pellier, Fanny Fouyssac, Camille Vercasson, Maya Allouche, Carolina Brito De Azevedo, Felipe Suarez, Despina Moshous, Benedicte Neven, Marlene Pasquet, Eric Jeziorski, Nathalie Aladjidi, Nicolas Schleinitz, Caroline Thomas, Virginie Gandemer, Francoise Mazingue, Patrick Lutz, Olivier Hermine, Capucine Picard, Stephane Blanche, Gerard Michel, Alain Fischer
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2017)
Article
Cell Biology
Pascale Gerbaud, Jean Guibourdenche, Rafika Jarray, Marc Conti, Patricia Palmic, Stephanie Leclerc-Mercier, Julie Bruneau, Olivier Hermine, Yves Lepelletier, Francoise Raynaud
JOURNAL OF CELLULAR PHYSIOLOGY
(2018)
Article
Oncology
Xavier Thomas, Stephane de Botton, Sylvie Chevret, Denis Caillot, Emmanuel Raffoux, Emilie Lemasle, Jean-Pierre Marolleau, Celine Berthon, Arnaud Pigneux, Norbert Vey, Oumedaly Reman, Marc Simon, Christian Recher, Jean-Yves Cahn, Olivier Hermine, Sylvie Castaigne, Karine Celli-Lebras, Norbert Ifrah, Claude Preudhomme, Christine Terre, Herve Dombret
JOURNAL OF CLINICAL ONCOLOGY
(2017)
Review
Geriatrics & Gerontology
Dmitry Petrov, Colin Mansfield, Alain Moussy, Olivier Hermine
FRONTIERS IN AGING NEUROSCIENCE
(2017)
Letter
Hematology
Lucile Couronne, Gerard Tertian, Audrey Boutron, Veronique Picard, Hakim Ouled-Haddou, Patricia Hughes, Olivier Hermine, Claude Prehu, Gil Tchernia, Loic Garcon
AMERICAN JOURNAL OF HEMATOLOGY
(2017)
Article
Biophysics
Slim Azouzi, Hubert Santuz, Sandrine Morandat, Catia Pereira, Francine Cote, Olivier Hermine, Karim El Kirat, Yves Colin, Caroline Le Van Kim, Catherine Etchebest, Pascal Amireault
BIOPHYSICAL JOURNAL
(2017)
Article
Medicine, Research & Experimental
Antoine Seignez, Anne-Laure Joly, Killian Chaumonnot, Adonis Hazoume, Michel Sanka, Guillaume Marcion, Christophe Boudesco, Arlette Hammann, Renaud Seigneuric, Gaetan Jego, Patrick Ducoroy, Patrice Delarue, Patrick Senet, Cristina Castilla-Llorente, Eric Solary, Marie-Agnes Durey, Marie-Therese Rubio, Olivier Hermine, Evelyne Kohli, Carmen Garrido
Article
Oncology
Jocelyn Turpin, Sandrine Alais, Ambroise Marcais, Julie Bruneau, Anat Melamed, Nicolas Gadot, Yuetsu Tanaka, Olivier Hermine, Sandrine Melot, Romain Lacoste, Charles R. Bangham, Renaud Mahieux
Review
Oncology
Peter Valent, Cem Akin, Karin Hartmann, Gunnar Nilsson, Andreas Reiter, Olivier Hermine, Karl Sotlar, Wolfgang R. Sperr, Luis Escribano, Tracy I. George, Hanneke C. Kluin-Nelemans, Celalettin Ustun, Massimo Triggiani, Knut Brockow, Jason Gotlib, Alberto Orfao, Lawrence B. Schwartz, Sigurd Broesby-Olsen, Carsten Bindslev-Jensen, Petri T. Kovanen, Stephen J. Galli, K. Frank Austen, Daniel A. Arber, Hans-Peter Horny, Michel Arock, Dean D. Metcalfe
Article
Immunology
Bertrand Dunogue, Benoit Pilmis, Nizar Mahlaoui, Caroline Elie, Helene Coignard-Biehler, Karima Amazzough, Nicolas Noel, Helene Salvator, Emilie Catherinot, Louis-Jean Couderc, Harry Sokol, Fanny Lanternier, Fanny Fouyssac, Julie Bardet, Jacinta Bustamante, Marie-Anne Gougerot-Pocidalo, Vincent Barlogis, Agathe Masseau, Isabelle Durieu, Marc Lecuit, Felipe Suarez, Alain Fischer, Stephane Blanche, Olivier Hermine, Olivier Lortholary
CLINICAL INFECTIOUS DISEASES
(2017)
Article
Hematology
Marine Armand, Caroline Besson, Olivier Hermine, Frederic Davi
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
(2017)
Article
Dermatology
David Michonneau, Tony Petrella, Nicolas Ortonne, Saskia Ingen-Housz-Oro, Nathalie Franck, Stephane Barete, Maxime Battistella, Marie Beylot-Barry, Beatrice Vergier, Marc Maynadie, Christine Bodemer, Olivier Hermine, Martine Bagot, Nicole Brousse, Sylvie Fraitag
ACTA DERMATO-VENEREOLOGICA
(2017)